Rein Therapeutics, formerly known as Aileron Therapeutics, has announced a rebranding to reflect its strategic focus on developing therapies for orphan pulmonary and fibrosis indications. The company's common stock will begin trading on the Nasdaq under the ticker symbol "RNTX" effective January 13, 2025. This rebranding marks a new chapter for the company, underscoring its commitment to addressing the critical needs of underserved patients with fibrotic diseases.

Recent Clinical Achievements

LTI-03, a Caveolin-1 related peptide, has shown promising results in treating idiopathic pulmonary fibrosis (IPF). In November 2024, the company announced positive topline data from Cohort 2 of the Phase 1b clinical trial evaluating the safety and tolerability of inhaled high dose LTI-03 (5 mg BID) and a set of exploratory biomarkers in patients with IPF. Four biomarkers showed statistical significance in the combined Cohort 1 and Cohort 2 dataset, and five demonstrated dose dependence with respect to low dose (2.5 mg BID) Cohort 1, indicative of active pharmacodynamics. High dose LTI-03 continued to exhibit a favorable safety profile.

2024 Corporate Highlights

In March 2024, Brian Windsor, Ph.D., was appointed Chief Executive Officer of the Company, marking the Company's sole focus on advancing a pipeline of first-in-class therapies for orphan pulmonary and fibrosis indications. In May 2024, the Company completed an underwritten registered direct offering of its common stock and accompanying warrants raising net proceeds of approximately $17.7 million.

2025 Strategic Objectives and Anticipated Milestones

LTI-03: A Phase 2 trial of LTI-03 for the treatment of IPF is anticipated to be initiated in the first half of this year.

LTI-01: The Company's Phase 2b-ready asset is a first-in-class therapy for the treatment of loculated pleural effusions (LPEs). It holds Orphan Drug Designation for the treatment of pleural empyema in the U.S and E.U. and Fast Track Designation in the U.S.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit the company's website at reintx.com, or follow them on LinkedIn and X.

Forward-Looking Statements

This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the timing and expectation of a Phase 2 trial of LTI-03; and future expectations, plans and prospects for the Company. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors.



In conclusion, Rein Therapeutics' rebranding reflects its strategic focus on developing therapies for orphan pulmonary and fibrosis indications. The company's recent clinical and corporate achievements, as well as its key strategic objectives for 2025, position it as a promising player in the orphan pulmonary and fibrosis space. Investors should keep an eye on Rein Therapeutics as it continues to advance its pipeline and bring hope to patients affected by these underserved diseases.